Drug Profile


Alternative Names: BCX-1777; Fodosine; Forodesine hydrochloride; Immucillin-H

Latest Information Update: 07 Mar 2017

Price : $50

At a glance

  • Originator Albert Einstein College of Medicine; Industrial Research Limited
  • Developer BioCryst Pharmaceuticals; Mundipharma International
  • Class Antineoplastics; Antipsoriatics; Purine nucleosides; Pyrimidinones; Small molecules
  • Mechanism of Action Immunosuppressants; Purine nucleoside phosphorylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Hairy cell leukaemia; Cutaneous T cell lymphoma; Leukaemia; Acute lymphoblastic leukaemia; T cell prolymphocytic leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Peripheral T-cell lymphoma
  • Phase I Haematological malignancies
  • No development reported Chronic lymphocytic leukaemia; Cutaneous T cell lymphoma

Most Recent Events

  • 27 Feb 2017 Preregistration for Peripheral T-cell lymphoma in Japan (PO) before February 2017 (BioCryst Pharmaceuticals 10-K, February 2017)
  • 26 Feb 2016 Mundipharma announces intention to submit NDA to the Japanese Ministry of Health, Labor and Welfare (BioCryst Pharmaceutical, Form 10-K, February 2016)
  • 26 Feb 2016 Mundipharma completes a phase II trial in Peripheral T-cell lymphoma in Japan (BioCryst Pharmaceutical, Form 10-K, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top